Jun 29, 2007 - Voriconazole (VRC; Pfizer, Groton, CT), posaconazole. (PSC; Schering-Plough, Kenilworth, NJ), caspofungin (CAS;. Merck, Whitehouse Station ...
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2008, p. 357–360 0066-4804/08/$08.00⫹0 doi:10.1128/AAC.00856-07 Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Vol. 52, No. 1
Differential Activities of Newer Antifungal Agents against Candida albicans and Candida parapsilosis Biofilms䌤 〈spasia Katragkou,1 Athanasios Chatzimoschou,1 Maria Simitsopoulou,1 Maria Dalakiouridou,1 Eudoxia Diza-Mataftsi,2 Chaido Tsantali,3 and Emmanuel Roilides1* Laboratory of Infectious Diseases, Third Department of Pediatrics, Aristotle University, Hippokration Hospital, 54642 Thessaloniki, Greece1; First Department of Microbiology, Aristotle University, University Campus, 54124 Thessaloniki, Greece2; and First Department of Pediatrics, Aristotle University, Hippokration Hospital, 54642 Thessaloniki, Greece3 Received 29 June 2007/Returned for modification 21 August 2007/Accepted 6 October 2007
The activities of voriconazole, posaconazole, caspofungin, and anidulafungin against Candida albicans and Candida parapsilosis biofilms were evaluated. In contrast to planktonic cells, the MICs for voriconazole and posaconazole for the biofilms of the two species were high (>256 and >64 mg/liter, respectively) but relatively low for the echinocandins caspofungin and anidulafungin (
